The Claim
In adults with newly diagnosed Graves' disease, the addition of 500 mg L-carnitine and 83 mcg selenium to methimazole reduces cumulative methimazole exposure by 36% (from 101.6 to 65.3 mg×months) without compromising biochemical control.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults newly diagnosed with Graves' disease, taking 500 mg of L-carnitine and 83 mcg of selenium along with methimazole results in a 36% reduction in total methimazole exposure over time, without affecting the normalization of thyroid hormone levels.
See the scientific wording
In adults with newly diagnosed Graves' disease, adding 500 mg L-carnitine and 83 mcg selenium to methimazole reduces the cumulative methimazole exposure by 36% (from 101.6 to 65.3 mg×months), indicating a clinically meaningful reduction in long-term antithyroid drug burden without compromising biochemical control.
L-carnitine blocks thyroid hormones from entering cells and turning on metabolic genes, while selenium reduces inflammation and stops the immune system from making antibodies that overstimulate the thyroid. Together, they let the thyroid return to normal function faster, so less medication is needed to control hormone levels.
What the research says
1 studyPeople with Graves' disease who took L-carnitine and selenium along with their regular thyroid medicine needed less of the medicine overall, but still got just as well-controlled as those who took only the medicine.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.